3 Things You NEED to Know About PROLOTHERAPY - Does Science Support It?

Liz defines prolotherapy as 'proliferative therapy' designed to stimulate cellular division and tissue healing. She breaks down the standard injection cocktail: hypertonic dextrose as an osmotic irritant, lidocaine for local analgesia, and saline as a vehicle. By introducing high-concentration dextrose, clinicians induce acute local inflammation, which acts as the mandatory initial phase of connective tissue repair. The segment concludes by explaining how cellular proliferation gives way to tissue remodeling, emphasizing the role of targeted exercise during this phase.

• Prolotherapy triggers acute inflammation to kickstart cellular proliferation and tissue repair.
• Standard solutions blend hypertonic dextrose, lidocaine, and saline.
• Targeted physical rehabilitation during the remodeling stage is essential to build durable tissue.

Provides the foundational biological rationale behind how irritant solutions promote connective tissue repair.

This section covers advanced cellular modalities alongside dextrose, such as autologous platelet-rich plasma (PRP), bone marrow aspirate, and adipose-derived stem cells, which accelerate healing by directly delivering regenerative cells to the lesion. Liz then pivots to the clinical evidence, citing a systematic review by Bae et al. that demonstrated statistically significant pain reduction in chronic musculoskeletal conditions. These therapeutic effects persisted from six months to a year across pathologies like plantar fasciitis, rotator cuff tendinopathy, and osteoarthritis. When evaluated against isolated saline injections or standalone exercise, dextrose prolotherapy demonstrated distinct superiority by the one-month mark.

• Autologous options like PRP, bone marrow, and adipose grafts concentrate stem cells directly at the injury site.
• A systematic review by Bae et al. confirmed clinical pain relief lasting between six months and one year.
• Dextrose prolotherapy outperformed exercise therapy and saline controls within 30 days of treatment.

Outlines advanced cellular alternatives and cites peer-reviewed systematic reviews validating clinical efficacy.

Liz expands the scientific survey with additional major systematic reviews. She references Rotondo et al. (2020), which validated prolotherapy for repetitive stress and overuse injuries, notably Achilles, patellar, and plantar tendinopathies, finding significant gains in joint range of motion and pain reduction. She follows with Sit et al. (2016), which verified improved functional mobility and reduced pain in knee osteoarthritis compared to saline and exercise cohorts. Lastly, a 2021 review by Giordano et al. is cited to substantiate prolotherapy's efficacy in managing chronic low back conditions. The section closes with a critical assessment acknowledging that while findings are promising, broader high-quality randomized controlled trials are still needed to standardize precise dosages.

• Rotondo et al. (2020) confirmed prolotherapy increases functional range and reduces pain in overuse tendinopathies.
• Sit et al. (2016) demonstrated significant functional gains in knee osteoarthritis over saline and physical therapy.
• Giordano et al. (2021) documented clinical improvements for persistent low back pain.
• Further high-powered trials are required to standardize universal dosing and clinical application guidelines.

Synthesizes the specific clinical trials supporting prolotherapy for knees, backs, and overuse injuries.

Liz discusses the physiological threshold required for treatment, noting that solutions must feature a dextrose concentration of at least 10% to reliably elicit an inflammatory cascade. She details the typical procedural side effect profile, which remains mild: local post-injection pain, temporary bruising, transient numbness, and joint fullness. Liz directly compares prolotherapy to conventional corticosteroid injections, arguing that prolotherapy should be tried prior to steroids. She emphasizes that while steroids offer potent temporary analgesia, they compromise tendon and ligament tensile strength over time, unlike regenerative therapies that reinforce connective tissue.

• Dextrose concentrations of 10% or greater are required to provoke the intended therapeutic inflammatory response.
• Expected side effects are mild and self-limiting, including transient soreness, joint fullness, and bruising.
• Corticosteroids risk long-term structural degeneration of tendons and ligaments, making prolotherapy a preferable first-line regenerative candidate.

Delivers the critical clinical comparison between regenerative prolotherapy and catabolic corticosteroid therapies.

The brief concluding segment outlines provider qualifications, pointing out that regulations depend on regional medical governance. Focusing on Canada, Liz notes that licensed medical doctors, orthopaedic specialists, and certified naturopathic doctors with targeted injection training are legally authorized to deliver prolotherapy. She wraps up the presentation by inviting viewer engagement and concluding the discussion.

• Administration rules vary by jurisdiction; in Canada, medical doctors, specialists, and certified naturopaths may administer injections.
• Patients must ensure their practitioner possesses accredited specialty training in prolotherapy injection techniques.

Brief administrative note on jurisdictional provider credentials and sign-off.